Early recurrence and the need for re-resection following Photodynamic diagnosis–assisted Transurethral Resection of Bladder Tumours

Citation for published version:
for the UK PDD Users Group 2019, 'Early recurrence and the need for re-resection following Photodynamic diagnosis–assisted Transurethral Resection of Bladder Tumours: Multi-centre real-world experience of the UK PDD Users Group', Journal of Clinical Urology. https://doi.org/10.1177/2051415819890464

Digital Object Identifier (DOI):
10.1177/2051415819890464

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Journal of Clinical Urology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Early recurrence and the need for re-resection following Photodynamic diagnosis–assisted Transurethral Resection of Bladder Tumours: Multi-centre real-world experience of the UK PDD Users Group

Paramananthan Mariappan1, Colin Bunce2, Jo Cresswell3, Altaf Shamsuddin4, Malcolm Crundwell5, Roland Donat1, Rhidian A Hurle6, Alexandra Zachou2, Sarah Stewart1, Louise J Hartley1 and Hugh Mostafid7 for the UK PDD Users Group

Abstract
Objective: This study aimed to investigate the association between Photodynamic Diagnosis (PDD) with hexaminolevulinate (HAL) and the rate of complete resection and disease persistence at first follow-up cystoscopy for non-muscle-invasive bladder cancer (NMIBC) in UK real-world practice.
Methods: Audit data were pooled from six UK centres where HAL PDD was used in patients with a new NMIBC diagnosis undergoing transurethral resection of bladder tumours (TURBT) since 2008. Patients received adjunctive intravesical therapy and surveillance in line with European and UK guidelines, including early re-resection in high-grade NMIBC.
Results: PDD-assisted TURBT was done in 837 patients with new NMIBC. The detrusor muscle was present in 69.4% of cases. At early re-TURBT in 207 high-risk patients, 13.0% had residual disease. Multifocal disease was the most significant factor in increasing the rate of residual disease (odds ratio excluding cases of CIS=4.1; 95% confidence interval 1.5–11.3). The recurrence rate at first follow-up cystoscopy (RRFFC) was 10.6% (8.9% in patients with complete initial TURBT). In the historical cohort undergoing good-quality white-light TURBT, RRFFC was 31%; 40.5% of high-risk patients had residual disease at early re-TURBT.
Conclusion: HAL PDD may increase the rates of complete resection, reducing the risk of early recurrence and the need for routine re-resection in high-grade NMIBC.
Level of evidence: 2b.

Keywords
Fluorescence cystoscopy, hexaminolevulinate, recurrence, transitional cell carcinoma, urinary bladder neoplasms, urothelial carcinoma

Date received: 5 August 2019; accepted: 22 October 2019
Introduction

Transurethral resection of bladder tumours (TURBT) is the mainstay of treatment for non-muscle-invasive bladder cancer (NMIBC). Although, the intention of such treatment is curative, recurrence rates are high, necessitating regular and often prolonged follow-up. As a result, bladder cancer places a heavy and long-term burden on health-care resources and on patients.

The European Association of Urology recommends repeat TURBT after two to six weeks for patients at high risk of recurrence. For example, the prevalence of tumour persistence in patients with Ta and T1 tumours has been reported at approximately 39–47%. However, a blanket policy of early re-resection is burdensome for service providers and patients alike. We believe that the rate of residual disease after initial resection could be reduced by emphasising better-quality initial TURBT, thus obviating the need for default early re-resection in every high-risk case.

Clinical trials and real-world experience show that use of photodynamic diagnosis (PDD; also known as fluorescence cystoscopy) increases detection of tumours, especially carcinoma in situ (CIS), compared to white-light cystoscopy (WLC) alone and improves clearance of tumour margins. Long-term follow-up of the largest randomised clinical trial of hexaminolevulinate (HAL) indicates that this improved detection translates into a clinically significant reduction in recurrence-free survival, with a trend towards reduced progression rates compared to WLC.

To date, there is limited evidence on the role of HAL PDD in reducing residual disease at early re-TURBT, with one single-centre study (N=446) indicating a significant reduction in recurrence rate at the six-week re-TURBT from 31.2% with WLC to 11.1% with PDD (p=0.0001). The objective of the present analysis was to describe residual disease rates and recurrence in a large population of patients, using pooled audit data from an ongoing collaboration between urological teams at seven centres across the UK.

Methods

Data were collected as an audit of outcomes/quality prospectively (Edinburgh) or retrospectively (Barnet, Middlesbrough, Exeter, Bridgend and Basingstoke) on all new NMIBC patients receiving HAL PDD-guided cystoscopy or TURB-T from 2008 until May 2011 in the participating centres, with analysis focusing on risk of residual disease at early re-TURBT in patients with high-grade NMIBC, recurrence rate at the first follow-up cystoscopy (RRFFC) and comparison of the above end points between TURBT guided by PDD (PDD-TURBT) and TURBT performed under white-light (WL-TURBT) in a historical cohort from Edinburgh.

Medical procedures

Mitomycin C was given to all patients within 24 hours of initial resection in most centres unless contraindicated or if it was felt inappropriate by the clinician. Further intra-vascular instillation of mitomycin C or bacille Calmette–Guérin (BCG) in line with European and UK guidelines was dependent on local policy following discussion at the multidisciplinary meeting. None of the patients received BCG prior to the early re-TURBT, and a six-week course of mitomycin C was used in only one centre for 16 patients with intermediate-risk NMIBC.

In patients with high-grade NMIBC, re-TURBT was performed within six weeks of initial TURBT, and cystoscopy + biopsy was performed at three months where re-TURBT was felt inappropriate by the local team. High-grade NMIBC was defined according to the World Health Organization 1973 and 2004 classifications as high-grade (anaplastic) CIS or papillary urothelial carcinoma (PUC). All patients with low- to intermediate-risk NMIBC had the first check cystoscopy at three months. Completeness of resection post TURBT was assessed visually by the consultant carrying out the TURBT or by the supervising consultant if the TURBT procedure was carried out by a trainee.
after the resection. Detailed findings for this control group have been published previously.6,11

Results
In total, PDD-assisted surgery was carried out in 1127 patients, of whom 1008 had new bladder cancer of any stage (including stages T2–T4). The present analysis focuses on the 837 patients with new NMIBC, comprising 295 from Edinburgh, 192 from Basingstoke, 163 from Barnet, 85 from Middlesbrough, 64 from Exeter and 38 from Bridgend. The mean age of patients with newly diagnosed NMIBC was 70.5 years. Baseline demographics are described in Table 1.
Table 1. Patient demographics, tumour characteristics and surgeon category at first transurethral resection of the bladder for all patients with newly diagnosed NMIBC.

| Characteristics                                      | Patients, n (%) |
|------------------------------------------------------|-----------------|
| Patients with new NMIBC                              | 837             |
| NMIBC without tumour features recorded               | 192 (22.9)      |
| **Tumour size**                                      |                 |
| <5 mm                                                | 145 (22.5)      |
| 5–10 mm                                              | 139 (26.8)      |
| 10–30 mm                                             | 173 (21.6)      |
| >30 mm                                               | 188 (29.2)      |
| **Tumour multiplicity**                              |                 |
| Single                                               | 358 (63.9)      |
| 2                                                    | 90 (13.9)       |
| 3                                                    | 43 (6.7)        |
| >3                                                   | 154 (23.9)      |
| **Tumour appearance**                                |                 |
| Papillary                                            | 518 (80.3)      |
| Solid                                                | 28 (4.3)        |
| Mixed papillary and solid                            | 86 (13.3)       |
| Flat lesion (red patch or carpet like)               | 13 (2.0)        |
| **Primary grade (World Health Organization 1973 and 2004)** |             |
| G1 (including PUNLMP)                                | 233 (27.8)      |
| G2 (low-grade\(^a\) PUC)                            | 315 (37.6)      |
| G3 (includes high-grade\(^b\) G2)                   | 242 (28.9)      |
| G3+ CIS                                              | 22 (2.6)        |
| Primary CIS                                          | 25 (2.9)        |
| **Primary stage**                                    |                 |
| Ta                                                   | 593 (70.7)      |
| T1                                                   | 191 (22.8)      |
| Ta/T1 + Tis                                         | 21 (2.5)        |
| Tis                                                  | 25 (2.9)        |
| Tx                                                   | 7 (0.8)         |
| **Complete resection**                               |                 |
| Yes                                                  | 759 (90.7)      |
| No                                                   | 49 (5.9)        |
| Biopsy and diathermy                                 | 5 (0.6)         |
| Unsure                                               | 22 (2.6)        |
| **Detrusor muscle in specimen**                      |                 |
| Present                                              | 581 (69.4)      |
| Absent                                               | 233 (27.8)      |
| Not sure                                             | 23 (2.8)        |
| **Surgeon category**                                 |                 |
| Senior (consultant or trainee ≥5 years)              | 694 (82.9)      |
| Junior (trainee <5 years)                            | 117 (13.9)      |
| Unknown                                              | 26 (3.1)        |

\(^a\)Low-grade PUC defined as a neoplasm of urothelium lining papillary fronds which shows an orderly appearance but easily recognisable variations in architecture and cytologic features.

\(^b\)High-grade G2 (PUC) defined as a neoplasm of urothelium lining papillary fronds which shows a predominant pattern of disorder with moderate-to-marked architectural and cytologic atypia.

NMIBC: non-muscle-invasive bladder cancer; CIS: carcinoma in situ; PUC: papillary urothelial carcinoma; PUNLMP: papillary urothelial neoplasm of low malignant potential.
Overall, 759 (90.7%) patients with new NMIBC were deemed by the surgeon to have had a complete initial PDD-TURBT; the remainder had incomplete resection, were managed with biopsy and fulguration or the completeness of resection was uncertain. The detrusor muscle was present in 581 (69.4%) NMIBC cases.

At early re-TURBT, residual disease was found in 27 (13.0%) of 207 cases of high-grade NMIBC, with upstaging to T2 cancer in three (1.5%) cases. Table 2 describes the association between primary tumour features and risk of residual disease following initial complete PDD-TURBT for high-grade NMIBC.

The analysis includes data from 167 patients, of whom 154 had re-TURBT and 13 had cystoscopy in three months; excludes patients with primary CIS. PDD: photodynamic diagnosis; TURBT: transurethral resection of bladder tumours; OR: odds ratio; CI: confidence interval.

Table 2. Univariate and multivariate regression analysis to determine association between primary tumour features and risk of residual disease following initial complete PDD-TURBT for high-grade NMIBC.

| Variable          | Residual disease status, n (%) | OR (95% CI), p |
|-------------------|--------------------------------|----------------|
|                   | Present | Absent | Univariate | Multivariate |
| Tumour size       |         |         |            |              |
| Large (>3 cm)     | 11/69   | 58/69   | 1.2 (0.15–2.9), 0.7 | – |
| Small (≤3 cm)     | 13/98   | 85/98   |            |              |
| Tumour number     |         |         |            |              |
| 1–2               | 8/104   | 96/104  | 4.1 (1.5–11.3), 0.001 | 3.1 (1.3–9.5), <0.01 |
| ≥3                | 16/63   | 47/63   |            |              |
| Tumour appearance |         |         |            |              |
| Papillary         | 15/128  | 113/128 | 2.3 (0.8–6.2), 0.07 | – |
| Solid or mixed    | 9/39    | 30/39   |            |              |
| Pathological stage|         |         |            |              |
| pTa               | 7/75    | 68/75   | 2.2 (0.8–6.7), 0.1 | – |
| pT1               | 17/92   | 75/92   |            |              |

The analysis includes data from 167 patients, of whom 154 had re-TURBT and 13 had cystoscopy in three months; excludes patients with primary CIS. PDD: photodynamic diagnosis; TURBT: transurethral resection of bladder tumours; OR: odds ratio; CI: confidence interval.

Table 3. Recurrence rates at first follow-up cystoscopy (RRFFC) and at one year (RR-1y).

|                      | RRFFC, n/N (%) | RR-1y, n/N (%) |
|----------------------|----------------|----------------|
| Overall              | 85/801 (10.6)  | 41/225 (18.2)  |
| After complete PDD-TURBT | 65/730 (8.9)  | 38/209 (18.2)  |
| By recurrence risk   |                |                |
| Low                  | 7/185 (3.8)    | 3/63 (4.8)     |
| Intermediate         | 23/182 (12.6)  | 17/83 (20.5)   |
| High                 | 25/171 (14.6)  | 17/75 (22.7)   |

*aIncludes re-TURBT at two to six weeks for patients with high-grade disease and first follow-up visit at three months for patients with low- or intermediate-risk disease at the Edinburgh, Middlesbrough and Exeter centres.

Overall, 759 (90.7%) patients with new NMIBC were deemed by the surgeon to have had a complete initial PDD-TURBT; the remainder had incomplete resection, were managed with biopsy and fulguration or the completeness of resection was uncertain. The detrusor muscle was present in 581 (69.4%) NMIBC cases.

At early re-TURBT, residual disease was found in 27 (13.0%) of 207 cases of high-grade NMIBC, with upstaging to T2 cancer in three (1.5%) cases. Table 2 describes the association between primary tumour features and residual disease in patients with high-grade NMIBC, excluding those with CIS (n=167). Patients with multiple tumours, solid- or mixed-appearing tumours and T1 tumours appeared more likely to have residual disease following complete PDD-TURBT for high-grade NMIBC compared to the historical control group. Residual cancer was found in 22 (17.6%) of 125 patients with the detrusor muscle present in the specimen and in eight (19.1%) of 42 patients when the detrusor muscle was absent.

The overall RRFFC (including early re-TURBT for high-grade NMIBC) following complete PDD-TURBT was 8.9%. Table 3 describes RRFFC and recurrence rates at one year stratified by baseline recurrence risk groups. Respective end points in the historical control group of patients undergoing GQ-WLTURBT are shown in Table 4.

Discussion

This audit by the UK PDD Users Group has collected records from more than 1000 patients to date, providing the largest evidence base for HAL and for PDD in the UK, as well as being one of the largest patient pools globally. This collaboration represents the first multi-centre study in the UK to collect real-world data on recurrence/residual disease rates with HAL PDD.

In our study, RRFFC with PDD was 11%, the detrusor muscle was absent in only 31% of specimens and the residual disease rate was only 13% of high-grade NMIBC cases.
This is in line with the 11% residual disease rate observed with the use of advanced optical imaging tools in the study by Geavlete et al. and appears favourable in comparison to historical studies of early re-TURBT, where residual disease rates of up to 76% and rates of complete resection (including muscle) of 20–84% were observed.

This analysis is a single-arm audit, without a contemporary control group. However, the results can be considered in light of experiences at one of the centres (Western General Hospital), which offers a historical control group of patients managed by experienced urologists who were also involved in the present audit. Despite the GQ-WLTURBT, the RRFFC was 31%, with 40.5% residual disease at early re-TURBT in high-risk patients, and the detrusor muscle was absent in almost 40% of specimens.

The reduction in residual disease and recurrence rates could be attributed to: the high level of experience of the surgeons performing TURBT; good-quality training, with overall improved attention to detail and close supervision; dedicated lists for TURBT at participating centres; including the detrusor muscle in the specimen of 20–84% were observed.

The reduction in residual disease and recurrence rates could be attributed to: the high level of experience of the surgeons performing TURBT; good-quality training, with overall improved attention to detail and close supervision; dedicated lists for TURBT at participating centres; including the detrusor muscle in the specimen of 20–84% were observed.

The reduction in residual disease and recurrence rates could be attributed to: the high level of experience of the surgeons performing TURBT; good-quality training, with overall improved attention to detail and close supervision; dedicated lists for TURBT at participating centres; including the detrusor muscle in the specimen of 20–84% were observed.

This means that appropriate treatment is initiated without delay.

With such potential to improve detection and resection with PDD in the majority of patients, we hypothesise that the number of cases requiring early re-TURBT could be substantially reduced, allowing resources to be prioritised in the subgroups most likely to benefit. One such subgroup is those with multifocal disease, which was found to be the most significant factor in increasing the residual disease rate. Another subgroup that could benefit is those where the muscle is absent from the specimen. Indeed, in a large multi-centre cohort, Gontero et al. found that re-TURBT had no impact on recurrence, progression, cancer-specific survival or overall survival in cases where the muscle was present in the initial resection specimen. This has been shown to be an indicator of high-quality resection. The use of PDD could potentially reduce the burden of repeat surgery and its possible complications, including the risk of tumour seeding and spread, in other patient subgroups such as those with large lesions or only one or two stage T1 lesions. This approach would currently be at odds with international guidelines but, if validated by further research, could represent a new direction of travel to reduce the burden of NMIBC management on patients and health-care services.

We believe that we have provided an important foundation on which to build a long-term evidence base for the use of HAL PDD in the management of NMIBC. Our aim in the future is to try to standardise prospectively collected information on each PDD case across centres, so that, in time, we can undertake high-quality analyses of consistent data from as large a pool of patients as possible. We encourage all centres using HAL PDD to join this initiative, regardless of how much experience they currently have, as one of our aims is to show the increasing benefit of PDD over time, not just in terms of improving results versus WLC, but also because we believe that PDD can improve our surgical technique overall.

### Limitations

The audit results that we present here come from both prospectively and retrospectively collected data from different centres, with varying levels of experience using HAL PDD and with, in some cases, restrictions on the patients in whom HAL PDD is used. In addition, each centre initially set up its own methods of recording details for each patient. The heterogeneity of the data and limited information available for some of the factors that potentially influence

### Table 4. Outcomes after PDD-TURBT compared to findings in a control group of patients undergoing good-quality WL-TURBT at the Western General Hospital.

|                              | PDD-TURBT, n (%) | WL-TURBT,6 n (%) | Univariate OR (95% CI), p |
|------------------------------|------------------|------------------|--------------------------|
| Patients with newly diagnosed NMIBC | 837 (90.7)       | 302 (74.5)       | 3.3 (2.4–4.7), 0.001     |
| Complete initial TURBT       | 759 (69.4)       | 187 (61.9)       | 1.4 (1.1–1.8), 0.02      |
| Detrusor muscle in specimen  | 581 (13.0)       | 17/42 (40.5)     | 4.5 (2.2–9.5), <0.001    |
| Residual disease at early re-TURBT in patients with high-risk NMIBC | 27/207 (10.2) | 16/47 (34.0) | 4.6 (1.7–12.3), 0.002  |
| Upstaging after re-TURBT     | 3/207 (1.5)      | 2/44 (4.5)       | N/A (too small values)   |
| Overall RRFFC                | 85/801 (10.6)    | 48/155 (31.0)    | 3.8 (2.5–5.7), <0.001    |
| RRFFC in low-risk NMIBC      | 1/57 (0.02)      | 15/68 (22.1)     | N/A (too small values)   |
| RRFFC in intermediate-risk NMIBC | 7/69 (10.2)    | 16/47 (34.0)     | 4.6 (1.7–12.3), 0.002  |
outcome need to be borne in mind when considering our results. For example, data on the use of mitomycin C are only available from the Edinburgh centre, where 74% of patients received a single mitomycin C instillation within 24 hours of initial cystoscopy. Such challenges with data collection from multiple UK centres in relation to bladder cancer were also experienced in the BAUS radical cystectomy audit, where only 37% of in the Hospital Episode Statistics data were entered into the database with significant data heterogeneity.22

Conclusion
In conclusion, our audit data suggest the use of HAL PDD may improve bladder visualisation, thereby increasing the probability of complete resection and reducing the risk of recurrence. This was evident in this multi-centre audit across all risk groups, including those with high-grade or multifocal tumours or CIS. Further high-quality, prospective data collection across UK centres is needed to confirm this.

Conflicting interests
The authors declare that there is no conflict of interest.

Funding
The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: this collaboration was supported by Ipsen.

Ethical approval
This is an audit of practice and outcomes.

Informed consent
This is an audit of practice and outcomes.

Guarantor
All authors.

Contributorship
P. M. conceived the study and designed the pro forma for data collection, in collaboration with all authors. All authors were involved in data collection. P.M. carried out data analysis. P.M. wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

Acknowledgements
We would like to thank OPEN Health Medical Communications for assistance with the preparation of the article. The initial meetings of members of the UKPDD Users Group were made possible through financial support from GE Healthcare, Amersham, UK. The authors thank Sarah Etheridge PhD of Open Health Medical Communications, London, UK for providing medical writing support, which was funded by Ipsen SA in accordance with Good Publication Practice Guidelines. The authors retained editorial control over the content.

References
1. Babjuk M, Böhle A, Burger M, et al. European Association of Urology. Non-muscle-invasive Bladder Cancer, http://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/ (accessed 29 November 2016).
2. Leal J, Luengo-Fernandez R, Sullivan R, et al. Economic burden of bladder cancer across the European Union. Eur Urol 2016;69:438–447.
3. Vianello A, Costantini E, Del Zingaro M, et al. Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis. J Endourol 2011;25:1703–1712.
4. Lazica DA, Roth S, Brandt AS, et al. Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. Urol Int 2014;92:131–135.
5. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013;64:846–854.
6. Mariappan P, Rai B, El-Mokadem I, et al. Real-life experience: early recurrence with Hexvix photodynamic diagnosis-assisted transurethral resection of bladder tumour vs good-quality white light TURBT in new non-muscle-invasive bladder cancer. Urology 2015;86:327–331.
7. Palou J, Hernández C, Solsona E, et al. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study. BJU Int 2015;116:37–43.
8. Grossman HB, Stenzl A, Fradet Y, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188:58–62.
9. Kamat AM, Cookson M, Witjes JA, et al. The impact of blue light cystoscopy with hexaminolevulinate (HAL) on progression of bladder cancer – a new analysis. Bladder Cancer 2016;2:273–278.
10. Geavlete B, Jecu M, Multescu R, et al. HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer – re-TURBT recurrence rates in a prospective, randomized study. Urology 2010;76:664–669.
11. Mariappan P, Finney SM, Head E, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int 2012;109:1666–1673.
12. Shim JS, Choi H, Noh TI, et al. The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: results of a prospective study. Korean J Urol 2015;56:429–434.
13. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74–76.
14. Chamie K, Ballon-Landa E, Bassett JC, et al. Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link. Cancer 2015;121:379–385.
15. Badalato G, Patel T, Hruby G, et al. Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect the rate of upstaging in cT1 bladder cancer? BJU Int 2011;108:1292–1296.
16. Han KS, Joung JY, Cho KS, et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. *J Endourol* 2008;22:2699–2704.

17. Mariappan P, Zachou A and Grigor KM; of the Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. *Eur Urol* 2010;57:843–849.

18. Gontero P, Sylvester R, Pisano F, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. *BJU Int* 2016;118:44–52.

19. Mostafid AH. Time to re-evaluate and refine re-transurethral resection in bladder cancer? *BJU Int* 2016;118:9–10.

20. El-Abbady AA, Shoukry MS, Hanno AG, et al. Repeated transurethral resection of recurrent superficial bladder tumors – does it affect the spread and stage of the tumor? *Scand J Urol Nephrol* 2002;36:60–64.

21. Chang SS, Boorjian SA, Chou R, et al. American Urological Association. Non-muscle invasive bladder cancer, www.auanet.org/education/guidelines/non-muscle-invasive-bladder-cancer.cfm (accessed 2 October 2016).

22. Cresswell J, Mariappan P, Thomas S, et al. Radical cystectomy: analysis of trends in UK practice 2004–2012, from the British Association of Urological Surgeons’ (BAUS) Section of Oncology Dataset. *J Clin Urol* 2016;9:48–56.